Key Takeaways
- • The US Department of Justice and relators' bar are intensifying False Claims Act (FCA) enforcement actions in healthcare, with an emerging trend targeting not only portfolio companies but also private equity sponsors and firms themselves for alleged violations.
- • Private equity investors face expanding liability exposure under evolving FCA enforcement theories that extend culpability beyond traditional healthcare provider misconduct to include sponsor-level involvement and oversight failures.
- • Morgan Lewis is hosting a webinar on September 30, 2026, to address FCA compliance risks specific to healthcare private equity, offering practical mitigation strategies for sponsors and portfolio companies facing heightened regulatory scrutiny.
- • Institutional investors and PE firms should prioritize identification of key FCA risk areas within portfolio healthcare companies, with particular attention to sponsor-level governance, operational oversight, and compliance infrastructure as enforcement priorities shift.
Summary
Healthcare fraud enforcement continues as a top priority for federal regulators, but the regulatory landscape is shifting in ways that directly impact private equity investors and sponsors. Traditionally, False Claims Act actions have focused on healthcare providers themselves—hospitals, physician practices, and service organizations. However, recent enforcement trends reveal a more expansive approach: regulators and relators are increasingly targeting the private equity firms and sponsors that own or control these healthcare portfolio companies, viewing them as potentially liable parties for alleged FCA violations.
This expansion of liability theories creates material risk for alternative investment managers with healthcare sector exposure. The enforcement strategy reflects a regulatory perspective that treats PE sponsors as active participants in corporate governance and operational decision-making, rather than passive financial investors. Consequently, sponsors face scrutiny regarding compliance oversight, financial controls, coding and billing practices within portfolio companies, and the adequacy of internal compliance infrastructure.
Morgan Lewis, whose two-volume FCA treatise is regularly cited as authoritative by federal and state courts, is addressing these developments through a live webinar scheduled for September 30, 2026. The session will examine the specific liability theories driving the enforcement trend, identify key risk areas that sponsors and portfolio companies should monitor, and provide actionable mitigation strategies. CLE credit is pending approval in California, Florida, Illinois, New York, Pennsylvania, Texas, and Virginia, with reciprocal approval pending in Connecticut and New Jersey.
For institutional investors, family offices, and PE managers with healthcare allocations, this enforcement shift represents a material compliance consideration in due diligence, portfolio company governance, and exit planning. The widening regulatory net underscores the importance of robust compliance frameworks and proactive risk assessment within healthcare portfolio companies, particularly given the DOJ's stated enforcement priorities and the growing involvement of relators' counsel in identifying violations.
This expansion of liability theories creates material risk for alternative investment managers with healthcare sector exposure. The enforcement strategy reflects a regulatory perspective that treats PE sponsors as active participants in corporate governance and operational decision-making, rather than passive financial investors. Consequently, sponsors face scrutiny regarding compliance oversight, financial controls, coding and billing practices within portfolio companies, and the adequacy of internal compliance infrastructure.
Morgan Lewis, whose two-volume FCA treatise is regularly cited as authoritative by federal and state courts, is addressing these developments through a live webinar scheduled for September 30, 2026. The session will examine the specific liability theories driving the enforcement trend, identify key risk areas that sponsors and portfolio companies should monitor, and provide actionable mitigation strategies. CLE credit is pending approval in California, Florida, Illinois, New York, Pennsylvania, Texas, and Virginia, with reciprocal approval pending in Connecticut and New Jersey.
For institutional investors, family offices, and PE managers with healthcare allocations, this enforcement shift represents a material compliance consideration in due diligence, portfolio company governance, and exit planning. The widening regulatory net underscores the importance of robust compliance frameworks and proactive risk assessment within healthcare portfolio companies, particularly given the DOJ's stated enforcement priorities and the growing involvement of relators' counsel in identifying violations.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.